Alliance Global Partners analyst James Molloy downgraded BioCardia to Neutral from Buy and removed the firm’s price target following the recent Data Safety Monitoring Board pause on the BCDA-01 CardiAMP-HF trial for heart failure. The analyst noted that while it was not a stoppage for futility, “it is generally not a positive when a DSMB recommends pausing enrollment in a trial for any reason,” and the analyst believes this “increases the risks to BCDA-02 as well.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BCDA:
- Biotech Alert: Searches spiking for these stocks today
- BioCardia shares ‘oversold’ on news of trial pause, says H.C. Wainwright
- BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected
- BioCardia announces DSMB to pause new enrollment in Phase III CardiAMP trial
- BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan’s Pharmaceutical Medical Device Agency